The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry

Research Policy

Volumn 41, Issue 1, 2012, Pages 1-12

  Toole, Andrew A ^a,b  

^a ECONOMIC RESEARCH SERVICE   (United States)

^b CENTRE FOR EUROPEAN ECONOMIC RESEARCH ZEW   (Germany)

Author keywords

Biomedical; New molecular entities; NIH; Public science; R D; Research lags; Social return

Indexed keywords

BIOMEDICAL; MOLECULAR ENTITIES; NIH; PUBLIC SCIENCE; SOCIAL RETURN;

ECONOMICS; INDUSTRY; INNOVATION; INVESTMENTS;

INDUSTRIAL RESEARCH;

EID: 81855176240     PISSN: 00487333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.respol.2011.06.004     Document Type: Article

References (60)

1. D. Acemoglu, and J. Linn Market size in innovation: theory and evidence from the pharmaceutical industry Quarterly Journal of Economics 119 3 2004 1049 1090 (Pubitemid 39057314)
2. Z.J. Acs, D.B. Audretsch, and M.P. Feldman Real effects of academic research: comment American Economic Review 82 1 1991 363 367
3. J.D. Adams Fundamental stocks of knowledge and productivity growth Journal of Political Economy 98 4 1990 673 702
4. P. Aghion, and P. Howitt Growth with quality-improving innovations: an integrated framework P. Aghion, S. Durlauf, Handbook of Economic Growth vol. 1A 2005 Elsevier Amsterdam 67 110
5. A. Arundel, and A. Geuna Proximity and the use of public science by innovative European firms Economics of Innovation and New Technology 13 6 2004 559 580
6. M.N. Baily Research and development costs and returns: the U.S. pharmaceutical industry Journal of Political Economy 80 1 1972 70 85
7. C.F. Baum, M.E. Schaffer, and S. Stillman Enhanced routines for instrumental variables/generalized method of moments estimation and testing The Stata Journal 7 4 2007 465 506
8. M. Beise, and H. Stahl Public research and industrial innovations in Germany Research Policy 28 1999 397 422 (Pubitemid 129503958)
9. R. Blundell, R. Griffith, and J. Van Reenen Dynamic count data models of technological innovation The Economic Journal 105 429 1995 333 344
10. R. Blundell, R. Griffith, and J. Van Reenen Market share, market value and innovation in a panel of British manufacturing firms The Review of Economics and Studies 66 3 1999 529 554
11. R. Blundell, R. Griffith, and F. Windmeijer Individual effects and dynamics in count data models Journal of Econometrics 108 2002 113 131
12. R.A. Cerda Endogenous innovations in the pharmaceutical industry Journal of Evolutionary Economics 17 2007 473 515
13. I. Cockburn Is the pharmaceutical industry in a productivity crisis? A. Jaffe, J. Lerner, S. Stern, Innovation Policy and the Economy vol. 7 2006 MIT Press Cambridge, MA 1 32
14. I. Cockburn, and R. Henderson Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery Journal of Industrial Economics 156 2 1998 157 182
15. I. Cockburn, and R. Henderson Publicly funded science and the productivity of the pharmaceutical industry A. Jaffe, J. Lerner, S. Stern, Innovation Policy and the Economy vol. 1 2001 MIT Press Cambridge, MA 1 34
16. W.M. Cohen, R.R. Nelson, and J.P. Walsh Links and impacts: the influence of public research on industrial R&D Management Science 48 1 2002 1 23 (Pubitemid 34434352)
17. P. David, D. Mowery, and E.W. Steinmueller Analyzing the economic payoffs from basic research Economics of Innovation and New Technology 2 1992 73 90
18. J.A. DiMasi New drug development in the United States from 1963 to 1999 Clinical Pharmacology and Therapeutics 69 5 2001 286 296
19. J.A. DiMasi, R.W. Hansen, and H.G. Grabowski Cost of innovation in the pharmaceutical industry Journal of Health Economics 10 1991 107 142
20. J.A. DiMasi, R.W. Hansen, and H.G. Grabowski The price of innovation: new estimates of drug development costs Journal of Health Economics 22 2003 151 185 (Pubitemid 36279392)
21. H.P. Dustan, E.J. Roccella, and H.H. Garrison Controlling hypertension Archives of Internal Medicine 156 1996 1926 1935
22. A. Gambardella Science and Innovation: The US pharmaceutical industry during the 1980s 1995 Cambridge University Press Cambridge, MA
23. A. Gelijns, and N. Rosenberg The dynamics of technological change in medicine Health Affairs 13 3 1994 28 46 (Pubitemid 24252112)
24. C. Gourieroux, A. Monfort, and A. Trognon Pseudo maximum likelihood methods: applications to Poisson models Econometrica 52 3 1984 701 720
25. H. Grabowski, and J.M. Vernon Returns to R&D on new drug introductions in the 1980s Journal of Health Economics 13 1994 383 406
26. H. Grabowski, and J.M. Vernon Prospects for returns to pharmaceutical R&D under health care reform R.B. Helms, Competitive Strategies in the Pharmaceutical Industry 1996 The AEI Press Washington, D.C 194 207
27. Z. Griliches Research costs and social returns: hybrid corn and related innovations Journal of Political Economy 66 5 1958 419 431
28. Z. Griliches Issues in assessing the contribution of research and development to productivity growth Bell Journal of Economics 10 1 1979 92 116
29. Z. Griliches The search for R&D spillovers. Scandinavian Journal of Economics 94 Supplement 1992 S29 S47
30. Hall, B.H.; Cummins, C.; Laderman, E.S.; Mundy, J.; 1988. The R&D master file documentation. NBER technical working paper No. 72, December 1988.
31. R. Henderson The evolution of integrative capability: innovation in cardiovascular drug discovery Industrial and Corporate Change 3 3 1994 607 627
32. R. Henderson, and I. Cockburn Scale, scope and spillovers: the determinants of research productivity in the pharmaceutical industry RAND Journal of Economics 27 1 1996 32 59
33. A.B. Jaffe Real effects of academic research American Economic Review 79 5 1989 957 970
34. C. Jones, and A. Williams Measuring the social rate of return to R&D Quarterly Journal of Economics 113 4 1998 119 135
35. C.I. Jones Growth and ideas P. Aghion, S. Durlauf, Handbook of Economic Growth. vol. 1B 2005 Elsevier Amsterdam 1063 1111
36. A.K. Klevorick, R.C. Levin, R.R. Nelson, and S.G. Winter On the sources and significance of interindustry differences in technological opportunities Research Policy 24 1995 185 205
37. S. Malo The contribution of (not so) public research to commercial innovations in the field of combinatorial chemistry Research Policy 38 2009 957 970
38. E. Mansfield Academic research and industrial innovation Research Policy 20 1991 1 12
39. E. Mansfield Academic research and industrial innovation: an update of the empirical findings Research Policy 26 1998 773 776 (Pubitemid 128394436)
40. R.A. Maxwell, and S. Eckhardt Drug Discovery: A Case Book and Analysis 1990 Humana Press Clifton, NJ
41. G.S. McMillan, and R.D. Hamilton III The impact of publicly funded basic research: an integrative extension of Martin and Salter IEEE Transactions on Engineering Management 50 2 2003 184 191
42. S. Monjon, and P. Waelbroeck Assessing spillovers from universities to firms: evidence from French firm-level data International Journal of Industrial Organization 21 2003 1255 1270
43. F. Narin, K.S. Hamilton, and D. Olivastro The increasing linkage between U.S. technology and public science Research Policy 26 1997 317 330 (Pubitemid 127382138)
44. NIH Office of Director, 1997. Executive Summary: Director's Panel on Clinical Research Report, http://www.oenb.at/de/img/executive-summary - nih-directors-panel-on-clinical-research-report-12-97-tcm14-48582.pdf (last accessed February 24, 2011).
45. NIH, 2000. NIH contributions to pharmaceutical development, in: RX R&D myths: The case against the drug industry's R&D "scare card" (downloaded on 22 February 2011 from http://www.citizen.org/ documents/ACFDC.PDF.
46. Pharmaceutical Research and Manufacturers Association, Annual Survey Report. PhRMA: Washington D.C.; various years.
47. Reichert, J.M.; Milne, C-P.; 2002. Public and Private Sector Contributions to the Discovery and Development of 'Impact' Drugs. Tufts Center for the Study of Drug Development White Paper, May 2002.
48. A.J. Salter, and B.R. Martin The economic benefits of publicly funded basic research: a critical review Research Policy 30 2001 509 532 (Pubitemid 33674598)
49. B.N. Sampat, and F.R. Lichtenberg What are the respective roles of the public and private sectors in pharmaceutical innovation? Health Affairs 30 2 2011 332 339
50. F.M. Scherer, and D. Harhoff Technology policy for a world of skew-distributed outcomes Research Policy 29 2000 559 566
51. Scolnick, E.M.; 1990. Basic research and its impact on industrial R&D. The IRI Medalist's Address, Industrial Research Institute: Arlington, VA, May 1990.
52. S.C. Silverstein, H.H. Garrison, and S.J. Heinig A few basic economic facts about research in the medical and related life sciences The FASEB Journal 9 1995 833 840
53. A.A. Toole Does public scientific research complement private investment in research and development in the pharmaceutical industry? Journal of Law and Economics 50 2007 81 104
54. M. Trajtenberg Economic Analysis of Product Innovation: The Case of CT Scanners 1990 Harvard University Press Cambridge, MA
55. U.S. Congress, Office of Technology Assessment, Pharmaceutical R&D: Costs, Risks, and Rewards, OTA-H-522, Government Printing Office: Washington, D.C.; 1993.
56. S.N. Wiggins Product quality regulation and drug introductions Review of Economics and Statistics 63 1981 615 619
57. J.M. Wooldridge On the application of robust, regression-based diagnostics to models of conditional means and conditional variances Journal of Econometrics 47 1991 5 46
58. J.M Wooldridge Estimation and inference for dependent processes R.F. Engle, D.L. McFadden, Handbook of Econometrics vol. IV 1994 Elsevier Amsterdam
59. J.M. Wooldridge Quasi-likelihood methods for count data M.H. Pesaran, P. Schmidt, Handbook of Applied Econometrics vol. 2 1997 Blackwell Oxford, UK 352 406
60. Zycher, B.; DiMasi, J.A.; Milne, C-P.; 2008. Private sector contributions to pharmaceutical science: Thirty-five summary case histories," Center for Medical Progress, Manhattan Institute for Policy Research.